Chart-Typ:
Zeitraum:
| Johnson & Johnson Submits NDA For Icotrokinra In Plaque Psoriasis | NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) Monday said it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for icotrokinra for the treatment of... ► Artikel lesen |
| Johnson & Johnson seeks first icotrokinra U.S. FDA approval aiming to revolutionize treatment paradigm for adults and adolescents with plaque psoriasis | Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor
Filing based on unprecedented data package that... ► Artikel lesen |
| Johnson & Johnson Announces FDA Priority Review For TAR-200 NDA | NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced that the FDA granted Priority Review to the New Drug Application filed for TAR-200, an intravesical gemcitabine releasing system,... ► Artikel lesen |
| Biogen Inc.: Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025 | Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation for continued carePresentations on tau to explore its biological role, the... ► Artikel lesen |
| Biogen Announces Additional Investment In North Carolina's RTP | WESTON (dpa-AFX) - Biogen Inc. (BIIB) said it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park. In the next few years... ► Artikel lesen |
| Biogen Inc.: Biogen Announces $2 Billion Manufacturing Investment in North Carolina's Research Triangle Park in Conjunction with its 30th Anniversary | Investment builds on Biogen's 30-year history of manufacturing in the region, with approximately $10 billion invested to date CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq:... ► Artikel lesen |
| Ionis Pharmaceuticals: Spannender Ausblick | Das US-Biotechunternehmen Ionis Pharmaceuticals durchläuft derzeit eine hochspannende Phase. Ionis gilt als Pionier auf dem Gebiet der Antisense-Oligonukleotid-(ASO)-Technologie. In der Fachzeitschrift... ► Artikel lesen |
| Ionis Pharmaceuticals, Inc.: Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S. | - Agreement enables olezarsen to reach people living with conditions associated with elevated triglycerides across the world - - Ionis will continue to independently commercialize TRYNGOLZA (olezarsen)... ► Artikel lesen |
| Ionis Pharma Reports Approval Of WAINZUA In The EU | LONDON (dpa-AFX) - Ionis Pharmaceuticals (IONS) announced that Ionis and AstraZeneca's WAINZUA has been approved in the European Union for the treatment of hereditary transthyretin-mediated... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BG MEDICINE INC finden Sie auf Wallstreet Online.